Physician

Srinivasan Ramanuja, M.D.

According to 2025 Medicare claims, Srinivasan Ramanuja, M.D. (NPI: 1720184849) practices allergy/immunology in the Mankato, MN market, with the plurality of this provider's patient population coming from Blue Earth, MN. This provider's primary affiliated billing organization is MANKATO CLINIC LTD (NPI: 1629044029; TIN: 410849339) and primary practice location at 56001-6076. Ramanuja is affiliated with the Stratum Med ACO (ACO ID: A4527), participating under the MSSP model.

Ramanuja's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 92 traditional Medicare patients, billed 7,158 HCPCS/CPT codes, and received $208,665 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 1,032 prescription claims across 135 beneficiaries totaling $1,441,035 in drug costs, led by Orladeyo (Berotralstat Hydrochloride). DME data shows 65 claims. Open Payments data shows 31 records totaling $123,762. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $13,517 to $208,665. Similarly, Part D prescription costs have risen steadily, from $677,954 to $1,441,035. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $232 to $2,121.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	45	1,096	$13,517
2016	43	978	$11,433
2017	49	2,415	$46,897
2018	41	3,210	$73,982
2019	83	6,217	$145,405
2020	82	4,760	$123,308
2021	83	4,535	$118,087
2022	91	4,754	$129,663
2023	104	5,620	$171,240
2024	92	7,158	$208,665

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	77	590	$677,954
2016	74	583	$635,336
2017	80	614	$440,239
2018	75	632	$344,087
2019	81	668	$623,693
2020	95	740	$121,604
2021	100	813	$846,885
2022	107	828	$1,329,156
2023	117	951	$1,279,094
2024	135	1,032	$1,441,035

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	22	$123
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	14	$91
2023	N/R	20	$142
2024	N/R	65	$49,497

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	19	19	$128
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	63	92	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	24	28	$68
95004	Test for allergy using allergenic extract	13	587	$3
96160	Administration and interpretation of patient-focused health risk assessment	29	50	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Orladeyo	Berotralstat Hydrochloride	13	364	$533,813
Spiriva Respimat	Tiotropium Bromide	58	1,860	$31,503
Dulera	Mometasone/Formoterol	52	2,106	$24,225
Advair Hfa	Fluticasone Propion/Salmeterol	28	1,050	$14,876
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	37	1,650	$10,507

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1575	Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin	N	N/R	12	$48,518
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)	N	N/R	12	$518
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	N/R	13	$336
E0570	Nebulizer, with compressor	Y	N/R	15	$64
J7613	Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg	N	N/R	13	$60

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	17	$261	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	14	$123,501	GlaxoSmithKline, LLC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Srinivasan Ramanuja, M.D.?

Tedicare shows public-source Medicare data for Srinivasan Ramanuja, M.D. (NPI 1720184849), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Srinivasan Ramanuja, M.D. have ACO affiliation data?

Srinivasan Ramanuja, M.D. is shown with ACO affiliation data for Stratum Med ACO (MSSP, ACO ID A4527).

What billing organization is linked to Srinivasan Ramanuja, M.D.?

Srinivasan Ramanuja, M.D. is linked to MANKATO CLINIC LTD (billing NPI 1629044029) in the available physician profile data.

Does Srinivasan Ramanuja, M.D. have Open Payments data?

Srinivasan Ramanuja, M.D. has 31 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.